HASBROUCK HEIGHTS, N.J., June 15, 2010 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) announced today that the Company is nearing completion of a new multi-center U.S. long-term follow-up study of NX-1207, its investigational drug for the treatment of benign prostatic hyperplasia (BPH). Nymox expects to report final results and statistical analysis for the study in the next 1-2 weeks. The new study concerns assessment of the 48-60 month efficacy and benefits of a single treatment of NX-1207. Patients in the new study were followed and have remained blinded subsequent to their participation in Nymox's U.S. Study NX02-0014 in 2005-2006.

In the initial study's intent-to-treat cohort after 90 days, patients receiving the 2.5 mg dose of NX-1207 had a mean BPH Symptom Score improvement of 11.0 points, which was significantly better than the improvement shown by the placebo control group (p<.01). There were no significant side effects from NX-1207 in the trial. The initial study was undertaken in 2005-2006 at 43 U.S. sites and enrolled 175 subjects. The new study includes results from all currently available patients.

In multicenter U.S. clinical trials to date NX-1207 has been found to produce improvements in BPH symptom score that are approximately double that reported for currently approved BPH drugs without the side effects associated with those drugs, which can include sexual dysfunction, blood pressure changes and other adverse reactions. Results of follow-up studies of available subjects from NX-1207 clinical trials have provided evidence of durable benefits from NX-1207 treatment for up to 6½ years from the date of treatment.

BPH or enlarged prostate is one of the most commonly diagnosed diseases in the male U.S. population. The disorder affects approximately half of men over age 50 and close to 90% of men by age 80, and is associated with growth in prostate size as men age. BPH causes difficulties with urination associated with aging, such as urination at night, urge to void frequently, hesitancy, weak stream, and other problems.

More information about Nymox is available at www.nymox.com, email: info@nymox.com, or 800-936-9669.

This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.
CONTACT:  Nymox Pharmaceutical Corporation          Roy Wolvin          1-800-93NYMOX          www.nymox.com